Publisher's Synopsis
Human plasma pools used for the preparation of therapeutic products are known to carry a certain risk of transmitting viruses which cause diseases such as AIDS and hepatitis B and C. This volume brings the reader up to date with the efforts being made at all levels to ensure the safety of plasma-derived products. Emphasis is placed on the factors most important for product safety, such as donor selection, testing of individual units, control of the manufacturing process, the use of inactivation and/or elimination procedures, and end-product testing for infectious agents. Regulatory activities and the role of the WHO are also discussed. With contributions from leading experts, this volume is a valuable resource for all those concerned with the virological safety of plasma derivatives.
